EC Number |
Activating Compound |
Reference |
---|
2.3.1.135 | cellular retinol-binding protein |
CRBP, required for enzyme activity, CRBP-I and CRBP-III each compensate for the absence of the other, specifically in mammary tissue, adipose tissue, muscle, and heart |
674449 |
2.3.1.135 | cellular retinol-binding protein |
i.e. CRALBP, in presence of palmitoyl-CoA and CRALBP, Muller cell membranes synthesize 11-cis-retinyl ester from 11-cis-retinol at a rate which is 20fold higher than that of all-trans-retinyl ester, in absence of CRALBP, 11-cis-retinyl ester synthesis is greatly reduced by 7fold |
672075 |
2.3.1.135 | more |
activation and mRNA expression for LRAT is blocked completely in vivo by actinomycin D |
638614, 638624 |
2.3.1.135 | more |
activation is blocked completely in vivo by cycloheximide |
638614 |
2.3.1.135 | more |
retinoic acid must be continuously present to maintain LRAT gene expression in the ON position |
638624 |
2.3.1.135 | more |
the pollutant 2,3,7,8-tetrachlorodibenzo-4-dioxin, i.e. TCDD, induces enzyme expression in the kidney, induction mechanism, the expression of the cellular retinol binding protein I is unaffected, TCDD alters the retinoid metabolism regulation, expression and activity of cytochrome P450 A1 increases retinoic acid levels in kidney and liver, and enhances enzyme expression in the kidney |
658432 |
2.3.1.135 | N-(4-hydroxyphenyl)-retinamide |
necessary dose, 0.5 mg |
638616 |
2.3.1.135 | N-(4-hydroxyphenyl)-retinamide |
restores normal level of LRAT activity in vitamin A depleted rats |
638616 |
2.3.1.135 | retinoic acid |
- |
638619 |
2.3.1.135 | retinoic acid |
minimal dose for significant increase in LRAT activity and mRNA expression: 0.005 mg |
638624 |